Illumina, Inc. (ILMN) Shares Bought by Sivik Global Healthcare LLC
Sivik Global Healthcare LLC lifted its position in Illumina, Inc. (NASDAQ:ILMN) by 50.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 15,000 shares of the life sciences company’s stock after purchasing an additional 5,000 shares during the quarter. Sivik Global Healthcare LLC’s holdings in Illumina were worth $2,988,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Dupont Capital Management Corp bought a new position in Illumina in the third quarter valued at $153,000. Advisory Services Network LLC increased its stake in Illumina by 13.0% in the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after acquiring an additional 89 shares during the last quarter. Penserra Capital Management LLC increased its stake in Illumina by 13.0% in the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after acquiring an additional 102 shares during the last quarter. Paradigm Asset Management Co. LLC increased its stake in Illumina by 5.6% in the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after acquiring an additional 50 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. increased its stake in Illumina by 11.3% in the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after acquiring an additional 100 shares during the last quarter. 90.76% of the stock is currently owned by hedge funds and other institutional investors.
In other news, SVP Oene Mark Van sold 9,729 shares of the stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $211.33, for a total transaction of $2,056,029.57. Following the completion of the sale, the senior vice president now directly owns 24,908 shares in the company, valued at $5,263,807.64. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Michel Bouchard sold 616 shares of the stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $200.00, for a total transaction of $123,200.00. Following the sale, the chief accounting officer now owns 15,161 shares of the company’s stock, valued at $3,032,200. The disclosure for this sale can be found here. Insiders have sold 172,446 shares of company stock worth $35,486,114 over the last ninety days. Insiders own 0.89% of the company’s stock.
Shares of Illumina, Inc. (NASDAQ ILMN) traded up $3.30 during trading hours on Thursday, hitting $215.35. The stock had a trading volume of 692,100 shares, compared to its average volume of 954,919. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $215.96. The company has a market capitalization of $30,959.30, a PE ratio of 62.00, a P/E/G ratio of 3.50 and a beta of 0.74. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The firm had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. During the same period last year, the firm earned $0.97 earnings per share. The company’s revenue for the quarter was up 17.6% compared to the same quarter last year. research analysts expect that Illumina, Inc. will post 3.75 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Illumina, Inc. (ILMN) Shares Bought by Sivik Global Healthcare LLC” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/11/23/illumina-inc-ilmn-shares-bought-by-sivik-global-healthcare-llc.html.
A number of research firms recently commented on ILMN. Wells Fargo & Company reissued a “market perform” rating and issued a $205.00 target price (up previously from $200.00) on shares of Illumina in a research note on Wednesday, October 25th. Barclays PLC reissued an “equal weight” rating and issued a $150.00 target price on shares of Illumina in a research note on Wednesday, August 9th. First Analysis raised Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 target price on the stock in a research note on Wednesday, August 2nd. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Finally, Canaccord Genuity reissued a “hold” rating and issued a $170.00 target price on shares of Illumina in a research note on Wednesday, July 26th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. Illumina currently has an average rating of “Hold” and an average price target of $200.88.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.